SKY-0515 Placebo

Preclinical

SSkyhawk Therapeutics, Inc.

SKY-0515 Placebo is one of 18 therapeutic programs targeting Huntington disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Huntington DiseaseRecruiting

Huntington DiseasePreclinical

Recruiting

Competition

Competitive Landscape

18 competitors in Huntington Disease

#DrugCompanyPhaseTrials

Dojolvi

Epidiolex

Actigall

Risperdal

Haldol

Lithobid

SSolvay Pharmaceuticals

Approved

—7

Acetadote

AArbor Pharmaceuticals, Inc.

Minocin

Tasigna

AAzurity Pharmaceuticals

Approved

—10

Rilutek

AAzurity Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Huntington Disease

NCT07378644

Clinical

Trials by Indication[1]

Huntington disease1 trial

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

Recruiting·SSkyhawk Therapeutics, Inc.·Preclinical·NCT07378644·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SKY-0515 Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for SKY-0515 Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Skyhawk Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SSkyhawk Therapeutics, Inc.

SKY-0515 Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Huntington disease1 trial

References

Drug Info

Quick Facts

Related News